1文献来源de Castro G Jr,Kudaba I,Wu YL,et al. Fiveyear outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with nonsmall-cell lung cancer and programmed death ligand-1tumor proportion sc...1文献来源de Castro G Jr,Kudaba I,Wu YL,et al. Fiveyear outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with nonsmall-cell lung cancer and programmed death ligand-1tumor proportion score≥1%in the KEYNOTE-042 study[J]. J Clin Oncol,2023,41(11):1986-1991.2证据水平1b。展开更多
文摘1文献来源de Castro G Jr,Kudaba I,Wu YL,et al. Fiveyear outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with nonsmall-cell lung cancer and programmed death ligand-1tumor proportion score≥1%in the KEYNOTE-042 study[J]. J Clin Oncol,2023,41(11):1986-1991.2证据水平1b。